165 related articles for article (PubMed ID: 29730433)
1. The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patients.
Sthoeger Z; Sharabi A; Asher I; Zinger H; Segal R; Shearer G; Elkayam O; Mozes E
Clin Immunol; 2018 Jul; 192():85-91. PubMed ID: 29730433
[TBL] [Abstract][Full Text] [Related]
2. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
[TBL] [Abstract][Full Text] [Related]
3. The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients.
Sthoeger ZM; Sharabi A; Dayan M; Zinger H; Asher I; Sela U; Mozes E
Hum Immunol; 2009 Mar; 70(3):139-45. PubMed ID: 19280712
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1.
Sthoeger Z; Sharabi A; Zinger H; Asher I; Mozes E
Clin Immunol; 2018 Dec; 197():34-39. PubMed ID: 30170030
[TBL] [Abstract][Full Text] [Related]
5. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus.
Sthoeger Z; Zinger H; Sharabi A; Asher I; Mozes E
PLoS One; 2013; 8(3):e60394. PubMed ID: 23555966
[TBL] [Abstract][Full Text] [Related]
6. Interferon-β inhibits inflammatory responses mediators via suppression of iNOS signaling pathway in PBMCs from patients with primary Sjögren's syndrome.
Benchabane S; Belkhelfa M; Belguendouz H; Zidi S; Boudjelida A; Youinou P; Touil-Boukoffa C
Inflammopharmacology; 2018 Oct; 26(5):1165-1174. PubMed ID: 29869303
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of increased TRAF6 expression in the peripheral mononuclear cells of patients with primary Sjögren's syndrome by an EBV-EBER1-specific synthetic single-stranded complementary DNA molecule.
Sipka S; Zilahi E; Papp G; Chen JQ; Nagy A; Hegyi K; Kónya J; Zeher M
Int J Rheum Dis; 2017 May; 20(5):614-621. PubMed ID: 28470929
[TBL] [Abstract][Full Text] [Related]
8. Differential cytokine expression and regulatory cells in patients with primary and secondary Sjögren's syndrome.
Furuzawa-Carballeda J; Sánchez-Guerrero J; Betanzos JL; Enriquez AB; Avila-Casado C; Llorente L; Hernández-Molina G
Scand J Immunol; 2014 Dec; 80(6):432-40. PubMed ID: 25346207
[TBL] [Abstract][Full Text] [Related]
9. Differential interleukin (IL)-10 and IL-13 gene expression in vivo in salivary glands and peripheral blood mononuclear cells from patients with primary Sjögren's syndrome.
Villarreal GM; Alcocer-Varela J; Llorente L
Immunol Lett; 1996 Jan; 49(1-2):105-9. PubMed ID: 8964596
[TBL] [Abstract][Full Text] [Related]
10. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses.
Sela U; Dayan M; Hershkoviz R; Cahalon L; Lider O; Mozes E
Eur J Immunol; 2006 Nov; 36(11):2971-80. PubMed ID: 17051618
[TBL] [Abstract][Full Text] [Related]
11. Phagocyte-specific S100A8/A9 is upregulated in primary Sjögren's syndrome and triggers the secretion of pro-inflammatory cytokines in vitro.
Nicaise C; Weichselbaum L; Schandene L; Gangji V; Dehavay F; Bouchat J; Balau B; Vogl T; Soyfoo MS
Clin Exp Rheumatol; 2017; 35(1):129-136. PubMed ID: 27749214
[TBL] [Abstract][Full Text] [Related]
12. Connection between the Gut Microbiome, Systemic Inflammation, Gut Permeability and FOXP3 Expression in Patients with Primary Sjögren's Syndrome.
Cano-Ortiz A; Laborda-Illanes A; Plaza-Andrades I; Membrillo Del Pozo A; Villarrubia Cuadrado A; Rodríguez Calvo de Mora M; Leiva-Gea I; Sanchez-Alcoholado L; Queipo-Ortuño MI
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228011
[TBL] [Abstract][Full Text] [Related]
13. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome.
Chen Y; Wang Y; Xu L; Zhu W; Xu C; Xu M; Guo L; Hu W; Xu D; Jing R; Zhu Y; He J; Xu B
Int J Rheum Dis; 2019 Feb; 22(2):200-206. PubMed ID: 30338648
[TBL] [Abstract][Full Text] [Related]
14. Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.
Ciccia F; Guggino G; Rizzo A; Bombardieri M; Raimondo S; Carubbi F; Cannizzaro A; Sireci G; Dieli F; Campisi G; Giacomelli R; Cipriani P; De Leo G; Alessandro R; Triolo G
Clin Exp Immunol; 2015 Aug; 181(2):219-29. PubMed ID: 25880879
[TBL] [Abstract][Full Text] [Related]
15. Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis.
Katsifis GE; Rekka S; Moutsopoulos NM; Pillemer S; Wahl SM
Am J Pathol; 2009 Sep; 175(3):1167-77. PubMed ID: 19700754
[TBL] [Abstract][Full Text] [Related]
16. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
Mozes E; Sharabi A
Autoimmun Rev; 2010 Nov; 10(1):22-6. PubMed ID: 20659591
[TBL] [Abstract][Full Text] [Related]
17. The numbers of Foxp3 + Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjogren's syndrome.
Sarigul M; Yazisiz V; Bassorgun CI; Ulker M; Avci AB; Erbasan F; Gelen T; Gorczynski RM; Terzioglu E
Lupus; 2010 Feb; 19(2):138-45. PubMed ID: 19952070
[TBL] [Abstract][Full Text] [Related]
18. The role of M1/M2 macrophage polarization in primary Sjogren's syndrome.
Chen X; Zhu L; Wu H
Arthritis Res Ther; 2024 May; 26(1):101. PubMed ID: 38745331
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 1beta and tumour necrosis factor alpha secreting cells are increased in the peripheral blood of patients with primary Sjögren's syndrome.
Willeke P; Schotte H; Schlüter B; Erren M; Becker H; Dyong A; Mickholz E; Domschke W; Gaubitz M
Ann Rheum Dis; 2003 Apr; 62(4):359-62. PubMed ID: 12634239
[TBL] [Abstract][Full Text] [Related]
20. Increased CD200 levels in peripheral blood mononuclear cells of patients with primary Sjögren's syndrome.
Liu TT; Zeng XP; Gu ML; Deng AM
Int J Rheum Dis; 2020 May; 23(5):654-660. PubMed ID: 32180363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
